Navigation Links
Drug Found Ineffective Against Lung Disease
Date:6/30/2009

People with idiopathic pulmonary fibrosis gain no survival benefit, research finds,,

MONDAY, June 29 (HealthDay News) -- Treatment with interferon gamma-1b (Ifn-g1b) does not improve survival in people with a fatal lung disease called idiopathic pulmonary fibrosis, according to a study that was halted early after no benefit to participants was found.

Previous research had suggested that Ifn-g1b might benefit people with idiopathic pulmonary fibrosis, particularly those with mild to moderate disease.

The new study included 826 people, ages 40 to 79, who lived in Europe and North America. They were given injections of either 200 micrograms of Ifn-g1b (551 people) or a placebo (275) three times a week.

After a median of 64 weeks, 15 percent of those in the Ifn-g1b group and 13 percent in the placebo group had died. Symptoms such as flu-like illness, fatigue, fever and chills were more common among those in the Ifn-g1b group than in the placebo group. The two groups had similar rates of serious side effects, the researchers found.

"We cannot recommend treatment with interferon gamma-1b since the drug did not improve survival for patients with idiopathic pulmonary fibrosis, which refutes previous findings from subgroup analyses of survival in studies of patients with mild-to-moderate physiological impairment of pulmonary function," Dr. Talmadge E. King Jr., of the University of California, San Francisco, and colleagues wrote in the study published online and in an upcoming print issue of The Lancet.

The negative findings of this study "should be regarded as definite, [but] they should not discourage patients to participate in one of the several clinical trials currently underway to find effective treatments for this devastating disease," Dr. Demosthenes Bouros, of the Democritus University of Thrace in Greece, wrote in an accompanying editorial.

Bouros added that people deemed suitable "should be enrolled early in the transplantation list, which is today the only mode of treatment that prolongs survival."

More information

The U.S. National Heart, Lung and Blood Institute has more about idiopathic pulmonary fibrosis.



-- Robert Preidt



SOURCE: The Lancet, news release, June 29, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sudden Cardiac Arrest Foundation Mourns the Loss of Michael Jackson
2. The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors
3. New piece found in colorectal cancer puzzle
4. AUA Foundation announces 2009 Research Scholar Program award winners
5. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
6. Jennifer Dodson, M.D., named 2009 AUA Foundation/NIDDK/NCI Surgeon-Scientist Award winner
7. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
8. Elizabeth Edwards to Deliver Keynote Address at Patient Advocate Foundations 10th Annual Patient Congress
9. Virtuosant Technology Offers Virtuosant Foundation Portal™ for Free
10. The United Nations Foundation Joins White House Initiative to Encourage Public Service
11. Children's National Medical Center Honors The Children's Cancer Foundation for Commitment to Area Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Found Ineffective Against Lung Disease
(Date:5/23/2016)... ... ... Edward D. Buckingham, M.D . is excited announce that he has been ... out by the National Consumer Advisory Board to honor excellence in medicine. Only doctors ... award. , The National Consumer Advisory Board (NCAB) is a private organization created to ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical ... representatives from the Japan PMDA, US FDA, industry and academia at the ... help format data from clinical trials so that it can be shared and ...
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, ... host medical device summit on September 15 and 16, 2016 in San Diego, ... former FDA office bearers will be one of the largest gatherings of medical device ...
(Date:5/23/2016)... ... May 23, 2016 , ... In Pursuit of Balance (IPOB) co-founders Jasmine Hirsch ... operations at the end of 2016. , “We created IPOB to change the ... we look back on what we have achieved, we’re gratified by the response of ...
(Date:5/23/2016)... ... 2016 , ... Bio-Optronics, Inc. is delighted to announce recent ... recent and anticipated growth. , Max Elbaz was appointed as Vice President, Sales ... Max joined the Bio-Optronics team in March. His areas of expertise include international ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... , May 20, 2016 ... Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation ... Biological Drugs - This New Study Reveals Selling ... Ahead ,What is the future ... the latest technological and commercial analysis. Staying ahead ...
(Date:5/19/2016)... PARIS , May 19,2016 ... Activities at Digestive Disease Week Meeting and 91 ... Society Mauna Kea Technologies (Euronext: MKEA, ... laser endomicroscopy platform, today announced that its Cellvizio ... meeting focused on gastroenterology during the month of ...
(Date:5/19/2016)... , May 19, 2016 BioLight ... an emerging global ophthalmic company focused on the discovery, ... address ophthalmic conditions, announced today that it has obtained ... ) for the manufacturing, distribution, marketing and sales ... treatment of dry eye syndrome (DES) and other ophthalmic ...
Breaking Medicine Technology: